Copper complex

Claim 2

A compound which is a copper complex coordinated with a chiral Schiff base of the formula: ##STR8## wherein C is an asymmetric carbon atom, R 1 is selected from the group consisting of (a) alkyl groups whose carbon atom number is 1-10, and (b) aralkyl groups with or without alkoxy substituent(s), whose total carbon atom number is 7-20, R 2 is selected from aryl groups with alkoxy substituent(s), whose total carbon atom number is 7-30, X is selected from the group consisting of (a) hydrogen, (b) alkyl groups having 1-10 carbon atoms, (c) phenyl group, (d) alkoxy groups having 1-10 carbon atoms, (e) halogen atoms, (f) nitro, or X is benzo which together with the ring to which it is attached forms a naphthalene ring, and Y is a hydrogen atom.

Claim 3

A compound of claim 1 in which said copper complex has the following structure: ##STR9## wherein R 1 R 2 , X and Y are defined as in claim 1.

Claim 4

The compound of claim 1 in which said copper complex has the following structure: ##STR10## wherein C, R 1 , R 2 , X and Y are defined as in claim 1.

Claim 5

The compound of claim 1 in which R 1 is a. benzyl, b. 4-methoxyphenylmethyl, c. 4-isopropoxyphenylmethyl, d. 4-butoxyphenylmethyl, e. 4-benzyloxyphenylmethyl, f. methyl, g. isopropyl, h. isobutyl, or i. cyclohexylmethyl.

Claim 6

The compound of claim 1 in which R 2 is a. 2-methoxyphenyl, b. 2-ethoxyphenyl, c. 2-isopropoxyphenyl, d. 2-butoxyphenyl, e. 2-octyloxyphenyl, f. 2-benzyloxy-5-methylphenyl, p1 g. 2-butoxy-5-t-butylphenyl, h. 5-t-butyl-2-octyloxyphenyl, i. 4-butoxybiphenyl-3-yl, or j. 2,5-dibutoxyphenyl.

Claim 7

The compound of claim 2 in which said chiral Schiff base is either an (R)- or (S)-enantiomer of the following: a. N-salicylidene-2-amino-1,1-di(2-isopropoxyphenyl)-3-phenyl-1-propanol, b. N-salicylidene-2-amino-1,1-di(2-butoxy-5-t-butylphenyl)-3-phenyl-1-propanol, c. N-salicylidene-2-amino-1,1-di(2-methoxyphenyl)-3-phenyl-1-propanol, d. N-salicylidene-2-amino-1,1-di(2-ethoxyphenyl)-3-phenyl-1-propanol, e. N-salicylidene-2-amino-1,1-di(2-butoxyphenyl)-3-phenyl-1-propanol, f. N-salicylidene-2-amino-1,1-di(2-octyloxy-phenyl)-3-phenyl-1-propanol, g. N-salicylidene-2-amino-1,1-di(2-phenoxyphenyl)-3-phenyl-1-propanol, h. N-salicylidene-2-amino-1,1-di(2-benzyloxy-5-methylphenyl)-3-phenyl-1-propanol, i. N-salicylidene-2-amino-1,1-di(5-t-butyl-2-isopropoxyphenyl)-3-phenyl-1-propanol, j. N-salicylidene-2-amino-1,1-di(5-t-butyl-2-octyloxyphenyl)-3-phenyl-1-propanol, k. N-salicylidene-2-amino-1,1-di(4-butoxybiphenyl-3-yl)-3-phenyl-1-propanol, l. N-salicylidene-2-amino-1,1-di(2,5-dibutoxy-phenyl)-3-phenyl-1-propanol, m. N-salicylidene-2-amino-1,1-di(2-isopropoxyphenyl)-3-(4-isopropoxyphenyl)-1-propanol, n. N-salicylidene-2-amino-1,1-di(5-t-butyl-2-octyloxyphenyl)-3-(4-isopropoxyphenyl)-1-propanol, o. N-salicylidene-2-amino-1,1-di(2-butoxyphenyl)-3-cyclohexyl-1-propanol, p. N-salicylidene-2-amino-1,1-di(2-methoxyphenyl)-4-methyl-1-pentanol, q. N-salicylidene-2-amino-1,1-di(2-butoxy-5-t-butylphenyl)-4-methyl-1-pentanol, r. N-salicylidene-2-amino-1,1-di(2-benzyloxy-5-t-butylphenyl)-4-methyl-1-pentanol, s. N-salicylidene-2-amino-1,1-di(2-butoxy-5-t-butylphenyl)-1-propanol, t. N-salicylidene-2-amino-1,1-di(2-butoxyphenyl)-3-methyl-1-butanol, u. N-salicylidene-2-amino-1,1-di(2-butoxyphenyl)-1-propanol, v. N-(3,5-dibromosalicylidene)-2-amino-1,1-di(2-isopropoxyphenyl)-3-phenyl-1-propanol, w. N-(3-ethoxysalicylidene)-2-amino-1,1-di(2-isopropoxyphenyl)-3-phenyl-1-propanol, x. N-(2-hydroxy-1-naphthylmethylene)-2-amino-1,1-di(2-isopropoxyphenyl)-3-phenyl-1-propanol, or y. N-salicylidene-2-amino-1,1-di(4-butoxybiphenyl-3-yl)-1-propanol.

Claim 8

The compound of claim 3 in which said chiral Schiff base is either an (R)- or (S)-enantiomer of the following: a. N-salicylidene-2-amino-1,1-di(2-methoxyphenyl)-3-phenyl-1-propanol, b. N-salicylidene-2-amino-1,1-di(3-methoxyphenyl)-3-phenyl-1-propanol, or c. N-salicylidene-2-amino-1,1-di(2-methoxyphenyl)-4-methyl-1-pentanol.